How Much Does Jatenzo Cost in New Jersey in 2026?

Jatenzo Retail and Cash-Pay Pricing in New Jersey

The average cash-pay price for Jatenzo at New Jersey retail pharmacies sits near $900 per month in 2026, consistent with Tolmar's manufacturer list price. That figure applies to patients filling without insurance or a discount card. Prices vary by pharmacy location, with independent pharmacies in South Jersey sometimes pricing 5% to 10% below large chain retailers.

Jatenzo received FDA approval in March 2019 as the first oral testosterone undecanoate for adult males with hypogonadism caused by specific medical conditions. The prescribing information specifies a starting dose of 237 mg taken twice daily with a meal containing fat, because the drug's lymphatic absorption pathway depends on dietary lipid [1]. The key trial by Swerdloff et al. (2020) enrolled 166 hypogonadal men and showed that 87% of patients achieved eugonadal testosterone levels (300 to 1,100 ng/dL) at the final titrated dose over 52 weeks.

A single-month supply at $900 amounts to $10,800 annually before any discount, savings program, or insurance benefit. For self-pay patients, that number makes cost-reduction strategies critical.

The drug is classified as a Schedule III controlled substance under the Controlled Substances Act, which means New Jersey prescribers must hold an active DEA registration and comply with the state's Prescription Monitoring Program (PMP) requirements when writing each fill.

Insurance Coverage for Jatenzo in New Jersey

Most commercial health plans in New Jersey place Jatenzo on a specialty or non-preferred brand tier, resulting in copays between $50 and $150 per month before manufacturer assistance. Coverage policies typically require documentation of two confirmed low morning testosterone levels below 300 ng/dL, consistent with the Endocrine Society 2018 guideline threshold. Plans frequently also require a documented reason why topical or injectable testosterone is unsuitable, such as gel transfer risk to household contacts or needle phobia.

Horizon Blue Cross Blue Shield, the largest commercial insurer in New Jersey, lists Jatenzo under its specialty pharmacy benefit. Prior authorization requires the prescribing clinician to confirm a pathological cause of hypogonadism rather than age-related decline, aligning with the FDA-mandated indication and the Endocrine Society's clinical practice guideline.

Aetna and UnitedHealthcare, which serve large employer groups across the state, maintain similar step-therapy requirements. A 2020 analysis published in Urology found that prior authorization rejection rates for branded testosterone products exceeded 30% in commercial plans nationally, highlighting the importance of thorough documentation by the ordering provider.

Patients whose appeals are denied can file a complaint with the New Jersey Department of Banking and Insurance, which oversees health plan compliance in the state. The appeal must be filed within 60 days of the denial letter.

New Jersey Medicaid Coverage and Prior Authorization

New Jersey Medicaid covers Jatenzo with prior authorization. The PA process requires confirmation that the patient has a pathological etiology of hypogonadism, at least two morning serum testosterone readings below 300 ng/dL, and documentation that alternative formulations are contraindicated or have failed. Approval periods typically run 12 months before renewal is needed.

The Endocrine Society's 2018 guideline recommends testosterone therapy only when symptoms accompany biochemically confirmed deficiency, and New Jersey Medicaid formulary criteria reflect this threshold. Medicaid managed care organizations (MCOs) operating in New Jersey, including Amerigroup and WellCare, apply their own utilization management on top of the state's preferred drug list, so approval timelines may differ between MCOs.

For Medicaid beneficiaries in NJ, the out-of-pocket cost after PA approval is generally $0 to $3 per fill, depending on the MCO and plan tier. Patients enrolled in Medicaid cannot combine manufacturer copay cards with their benefit, because federal anti-kickback rules prohibit such stacking for government-funded insurance programs.

The Tolmar Savings Card: How It Works in New Jersey

Tolmar Pharmaceuticals offers a manufacturer savings card that reduces the out-of-pocket cost for commercially insured patients to as low as $0 per month, with a maximum annual benefit typically capped at $7,200 to $9,600 depending on the program year. The card is not valid for patients using Medicare, Medicaid, Tricare, or any other federal or state government-funded program.

To activate the card, patients register through the Tolmar patient portal or receive enrollment from their prescriber's office. The pharmacy processes the card as a secondary payer after the primary insurance adjudicates the claim. If the primary plan's copay is $75, for example, the savings card covers that amount in full.

A key limitation: the savings card applies only to the patient's cost-sharing portion, not the full retail price. A patient without insurance coverage cannot use the card to offset the entire $900 monthly cost. This structure follows the standard manufacturer copay assistance model described in pharmacy benefit research showing such programs increase brand adherence but do not function as direct-to-patient discounts for uninsured individuals.

New Jersey does not have a state law prohibiting accumulator adjustment programs, so some large employer plans may apply Tolmar card payments without crediting them toward the patient's deductible. Patients should ask their HR department or plan administrator whether an accumulator or maximizer program is in effect before relying on the card for the full year.

Compounded Oral Testosterone Undecanoate in New Jersey

Licensed 503A compounding pharmacies in New Jersey can prepare oral testosterone undecanoate capsules pursuant to a patient-specific prescription. This is legal under both federal law (FDCA Section 503A) and New Jersey Board of Pharmacy regulations, provided the pharmacy holds current licensure.

Compounded formulations cost substantially less than brand Jatenzo, with reported prices ranging from $50 to $200 per month depending on the pharmacy and dose. The trade-off is that compounded products are not FDA-approved, do not undergo the same bioequivalence testing, and are not subject to the post-marketing cardiovascular safety monitoring that Tolmar conducts for the branded product.

The FDA's guidance on 503A compounding specifies that compounders may not produce copies of commercially available drugs unless the prescriber documents a clinical difference (such as an allergy to a Jatenzo excipient or a need for a dose strength not commercially manufactured). In practice, many 503A pharmacies in New Jersey compound testosterone undecanoate at customized dose strengths that differ from Jatenzo's fixed 158 mg and 237 mg capsules, which satisfies this clinical-difference requirement.

Patients considering compounded oral testosterone undecanoate should confirm the pharmacy's USP 795 compliance and verify current NJ Board of Pharmacy licensure. A 2021 study published in JAMA Internal Medicine found that compounded hormone therapy products varied significantly in potency, with some capsules containing 75% to 130% of the labeled dose.

Telehealth Prescribing of Jatenzo in New Jersey

New Jersey law permits telehealth prescribing of Jatenzo. The state's telehealth parity act (P.L. 2020, c.3) requires commercial insurers to cover telehealth-delivered services at the same reimbursement rates as in-person visits. Prescribers must hold an active New Jersey medical license or practice under the state's reciprocal telehealth provisions.

Because Jatenzo is a Schedule III controlled substance, the DEA requires an initial evaluation, but the 2023 DEA telehealth rule extension has continued to allow initial prescriptions via audio-video telehealth without a mandatory in-person visit. NJ-based telehealth platforms can order the required baseline labs (total testosterone, LH, FSH, PSA, hematocrit, lipid panel) through local Quest or Labcorp draw sites across the state.

The Endocrine Society recommends monitoring hematocrit at baseline, at 3 to 6 months, and annually during testosterone therapy. Oral testosterone undecanoate has shown a lower incidence of polycythemia compared to injectable testosterone cypionate in comparative data from the Swerdloff trial, which reported hematocrit elevations above 54% in only 1.2% of oral TU patients.

Comparing Jatenzo to Other Testosterone Formulations Available in NJ

Jatenzo is the only FDA-approved oral testosterone undecanoate capsule on the U.S. market. Tlando (also oral testosterone undecanoate) received FDA approval in 2022 and offers a second branded option, though its New Jersey retail availability remains limited as of mid-2026.

Injectable testosterone cypionate (200 mg/mL) costs $30 to $80 per month at New Jersey pharmacies and remains the most affordable option for TRT. Testosterone gel 1.62% (generic AndroGel) runs $50 to $150 per month for cash-pay patients. Jatenzo's $900 list price positions it as the most expensive option before discounts.

A 2021 meta-analysis in The Journal of Clinical Endocrinology & Metabolism evaluated cardiovascular safety across testosterone formulations and found no statistically significant difference in major adverse cardiovascular events (MACE) between oral, transdermal, and injectable routes. The TRAVERSE trial (Lincoff et al., NEJM 2023), the largest randomized cardiovascular safety trial of testosterone therapy (N=5,246), demonstrated non-inferiority of testosterone gel versus placebo for MACE, providing reassurance about the cardiovascular profile of TRT as a class.

For patients who prefer oral dosing but cannot afford branded Jatenzo, the compounded 503A pathway or the Tlando alternative may narrow the cost gap. Patients should discuss these options with their prescribing clinician to determine the best fit for their clinical profile and budget.

Strategies to Reduce Your Jatenzo Cost in New Jersey

The most effective path to reducing Jatenzo cost depends on insurance status. Commercially insured patients should apply for the Tolmar savings card before the first fill. Uninsured patients should explore compounded oral testosterone undecanoate through a licensed 503A pharmacy, which can reduce costs to $50 to $200 per month.

Additional cost-reduction strategies include:

• Dose optimization. Jatenzo dosing starts at 237 mg twice daily, but the label allows titration down to 158 mg twice daily if testosterone levels exceed 1,100 ng/dL. A lower dose means fewer capsules per fill, reducing cost at pharmacies that price per capsule count.
• 90-day fills. Some NJ pharmacies and mail-order services offer a per-unit discount on 90-day supplies, trimming 10% to 15% off the monthly rate.
• Patient assistance programs. Tolmar maintains a patient assistance program (PAP) for uninsured patients whose household income falls below 400% of the federal poverty level. Approved applicants receive Jatenzo at no cost.
• Pharmacy shopping. Prices vary by pharmacy. Independent pharmacies in Newark, Cherry Hill, and Princeton have historically priced Jatenzo 5% to 10% below national chain averages.

Regardless of strategy, regular lab monitoring remains non-negotiable. The Endocrine Society recommends PSA and hematocrit checks at 3 to 6 months after initiation and annually thereafter, and skipping these labs to save money creates clinical risk that no cost savings can justify.